Orion and Endo Pharmaceuticals enter risk-sharing oncology partnership
This article was originally published in Scrip
Executive Summary
Orion of Finland and Endo Pharmaceuticals of the US are pooling a number of early-stage oncology assets in a risk-sharing partnership that includes shared responsibility for product development, geographical division of marketing rights and cross-royalties on any sales in these territories.